| Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease (NCT01383083) | Maryknoll Medical Center | 2010-11-01 |
| The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain (NCT01260454) | University of Rochester | 2010-11-01 |
| Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide (NCT01092559) | Geno LLC | 2010-10-01 |
| Endothelial Function in Patients With Pulmonary Arterial Hypertension (NCT01317134) | Universitätsklinikum Hamburg-Eppendorf | 2010-10-01 |
| Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (NCT01054105) | Gachon University Gil Medical Center | 2010-10-01 |
| Tezosentan in Patients With Pulmonary Arterial Hypertension (NCT01094067) | Idorsia Pharmaceuticals Ltd. | 2010-09-01 |
| Efficacy of Ventavis Used in Real-life Setting. (NCT01355380) | Bayer | 2010-08-05 |
| A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers (NCT01172496) | United Therapeutics | 2010-08-01 |
| Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (NCT01268553) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2010-08-01 |
| ACT-293987 in Pulmonary Arterial Hypertension (NCT01112306) | Actelion | 2010-07-07 |
| Pulmonary Hypertension in Interstitial Lung Disease (NCT01443598) | Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires | 2010-07-01 |
| Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities (NCT01165476) | United Therapeutics | 2010-07-01 |
| Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) (NCT01179737) | Novartis Pharmaceuticals | 2010-07-01 |
| Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine (NCT01153386) | United Therapeutics | 2010-07-01 |
| Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety (NCT00796510) | Pfizer | 2010-07-01 |
| Auto-immunity and Pulmonary Arterial Hypertension (NCT01208792) | Assistance Publique - Hôpitaux de Paris | 2010-06-15 |
| Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension (NCT00964678) | Virginia Commonwealth University | 2010-06-01 |
| Ranolazine and Pulmonary Hypertension (NCT01174173) | Northwestern University | 2010-06-01 |
| The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil (NCT01131845) | United Therapeutics | 2010-05-01 |
| Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 (NCT01105117) | Actelion | 2010-05-01 |
| A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin (NCT00995566) | Pfizer | 2010-04-01 |
| Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography (NCT02028299) | George Washington University | 2010-04-01 |
| Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (NCT01117987) | Novartis Pharmaceuticals | 2010-04-01 |
| Epoprostenol for Injection in Pulmonary Arterial Hypertension (NCT01105091) | Actelion | 2010-03-01 |
| Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) (NCT00989963) | Lung Biotechnology PBC | 2010-02-01 |
| Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension (NCT01066845) | Eli Lilly and Company | 2010-01-01 |
| A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (NCT01042158) | Johns Hopkins University | 2010-01-01 |
| Coenzyme Q-10 and Pulmonary Arterial Hypertension (NCT01148836) | The Cleveland Clinic | 2010-01-01 |
| Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) (NCT01043627) | Mayo Clinic | 2009-12-01 |
| Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (NCT01106014) | Actelion | 2009-12-01 |
| Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) (NCT01445873) | Pfizer | 2009-12-01 |
| Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients (NCT00990314) | Lung Biotechnology PBC | 2009-11-30 |
| Effect of Food on the Pharmacokinetics of Oral Treprostinil (NCT00963001) | United Therapeutics | 2009-09-01 |
| Imatinib (QTI571) in Pulmonary Arterial Hypertension (NCT00902174) | Novartis Pharmaceuticals | 2009-09-01 |
| Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension (NCT00942708) | University of Texas Southwestern Medical Center | 2009-09-01 |
| Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil (NCT00963027) | United Therapeutics | 2009-09-01 |
| Registry for Pulmonary Hypertension in China (NCT01417338) | Chinese Academy of Medical Sciences, Fuwai Hospital | 2009-08-01 |
| Biomarkers in the Evaluation of Chronic Lung Disease (NCT00926523) | Northwell Health | 2009-06-01 |
| Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension (NCT01391104) | Laval University | 2009-04-01 |
| Ventavis® Registry Protocol (NCT00902603) | Actelion | 2009-03-01 |
| An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients (NCT00792571) | Lung Biotechnology PBC | 2009-02-28 |
| A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients (NCT00781885) | Lung Biotechnology PBC | 2009-01-31 |
| Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) (NCT01100736) | University of Edinburgh | 2009-01-01 |
| Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) (NCT00832507) | Gilead Sciences | 2009-01-01 |
| Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers (NCT00814645) | Aires Pharmaceuticals, Inc. | 2008-12-01 |
| Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS) (NCT00795639) | Pfizer | 2008-12-01 |
| Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (NCT00667823) | Actelion | 2008-10-17 |
| Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) (NCT00706082) | Actelion | 2008-10-01 |
| Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (NCT00709098) | Actelion | 2008-09-01 |
| Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects (NCT00741819) | United Therapeutics | 2008-09-01 |
| Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. (NCT00705588) | Rabin Medical Center | 2008-08-01 |
| Iloprost Power Disc-15 in Pulmonary Arterial Hypertension (NCT00723554) | Actelion | 2008-07-01 |
| The Expression and Significance of MiRNA (NCT00806312) | Megan Ballinger | 2008-07-01 |
| Iloprost Power 15 in Pulmonary Arterial Hypertension (NCT00709956) | Actelion | 2008-07-01 |
| Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension (NCT00705133) | Rajan Saggar | 2008-07-01 |
| Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA) (NCT01181284) | Mayo Clinic | 2008-05-01 |
| Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension (NCT00660179) | Actelion | 2008-05-01 |
| Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH) (NCT00993408) | Actelion | 2008-04-30 |
| To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension. (NCT00430716) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2008-04-08 |
| Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension (NCT00581607) | University of Cincinnati | 2008-04-01 |
| Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) (NCT00617305) | Gilead Sciences | 2008-04-01 |
| 6R-BH4 Pulmonary Arterial Hypertension Study (NCT00435331) | Vanderbilt University | 2008-03-01 |
| Rehabilitation for Patients With Pulmonary Arterial Hypertension (NCT00544726) | Rabin Medical Center | 2008-02-01 |
| A Study to Evaluate GSK1325760A - a Long-Term Extension Study (NCT00554619) | GlaxoSmithKline | 2008-02-01 |
| Pulmonary Arterial Hypertension in Systemic Sclerosis (NCT00617487) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2007-12-01 |
| Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan (NCT00625469) | Rajan Saggar | 2007-10-01 |
| Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) (NCT00566423) | Northwell Health | 2007-05-01 |
| Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans (NCT00621075) | Northwell Health | 2007-04-01 |
| Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) (NCT00452218) | University of Chicago | 2007-03-01 |
| Combination Therapy in Pulmonary Arterial Hypertension (NCT00433329) | Actelion | 2007-03-01 |
| Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil (NCT00625079) | University of California, Los Angeles | 2007-02-01 |
| Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH (NCT00439946) | United Therapeutics | 2007-02-01 |
| An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (NCT01027949) | United Therapeutics | 2007-01-16 |
| Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension (NCT02885155) | Central Hospital, Nancy, France | 2007-01-01 |
| Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension (NCT00403650) | University of Cincinnati | 2006-11-01 |
| Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension (NCT00323297) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-09-01 |
| Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension (NCT00453414) | Actelion | 2006-07-01 |
| Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (NCT00303459) | Actelion | 2006-05-01 |
| Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension (NCT00477269) | Novartis Pharmaceuticals | 2006-04-01 |
| Bosentan in Children With Pulmonary Arterial Hypertension Extension Study (NCT00319020) | Actelion | 2005-08-23 |
| Pharmacogenomics in Pulmonary Arterial Hypertension (NCT00593905) | West Penn Allegheny Health System | 2005-07-01 |
| Bosentan in Children With Pulmonary Arterial Hypertension (NCT00319267) | Actelion | 2005-05-01 |
| Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension (NCT00494533) | United Therapeutics | 2005-03-01 |
| Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) (NCT00086463) | Actelion | 2004-06-01 |
| A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) (NCT00578786) | Gilead Sciences | 2004-02-01 |
| A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children (NCT00159874) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-01-01 |
| BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology (NCT00367770) | Actelion | 2004-01-01 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. (NCT00423202) | Gilead Sciences | 2003-12-01 |
| Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. (NCT00423748) | Gilead Sciences | 2003-12-01 |
| Hemodynamic Response After Six Months of Sildenafil (NCT00483626) | University of Chile | 2003-08-01 |
| A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (NCT00811018) | Pfizer | 2003-03-01 |
| A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension (NCT00058929) | United Therapeutics | 2002-10-01 |
| Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study (NCT00878943) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil (NCT01897740) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil (NCT00866983) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| An Open Label Access Study For Subjects Who Completed A1481156 (NCT01582438) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (NCT06939647) | Insmed Incorporated | |